Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
Clinical Lung Cancer · 2023
DOI: 10.1016/j.cllc.2023.05.003 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Lung Cancer, 2023. Verfasst von J Nicholas Bodor und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Genentech.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Patients with non-small-cell lung cancer (NSCLC) who have never smoked or have tumors with mutations in EGFR generally derive minimal benefit from single-agent PD-1/PD-L1 checkpoint inhibitors. Prior data indicate that adding PD-L1 inhibition to anti-VEGF and cytotoxic chemotherapy may be a promising approach to overcoming immunotherapy resistance in these patients, however prospective validation is needed. This trial in progress (NCT03786692) is evaluating patients with stage IV NSCLC who have never smoked or who have tumors with sensitizing EGFR alterations to determine if a 4-drug combination of atezolizumab, carboplatin, pemetrexed, and bevacizumab can improve outcomes compared to carboplatin, pemetrexed and bevacizumab without atezolizumab. METHODS: This is a randomized, phase II, multicenter study evaluating carboplatin, pemetrexed, bevacizumab with and without atezolizumab in 117 patients with stage IV nonsquamous NSCLC. Randomization is 2 to 1 favoring the atezolizumab containing arm. Eligible patients include: 1) those with tumors with sensitizing EGFR alterations in exons 19 or 21 or 2) patients who have never smoked and have wild-type tumors (ie, no EGFR, ALK or ROS1 alterations). Patients are defined as having never smoked if they have smoked less than 100 cigarettes in a lifetime. Patients with EGFR-mutated tumors must have disease progression or intolerance to prior tyrosine kinase inhibitor (TKI) therapy. The primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival (OS), response rate, duration of response, and time to response. CONCLUSION: This phase II trial is accruing patients at U.S. sites through the National Comprehensive Cancer Network (NCCN). The trial opened in August 2019 and accrual is expected to be completed in the Fall of 2024.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA.
- Hematology Oncology Division, Northwestern University, Chicago, IL.
- Department of Medical Oncology, Stanford Cancer Institute, Stanford, CA.
- Department of Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC.
- Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL.
- Department of Hematology/Oncology, University of Pennsylvania Abramson Cancer Center at Chester County Hospital, West Chester, PA.
Förderung
- NCI NIH HHS
- Genentech
Zitieren
APA
Bodor, J. N., Patel, J. D., Wakelee, H. A., Levy, B. P., Borghaei, H., Pellini, B., Costello, M. R., Dowell, J. E., Finley, G., Huang, C. H., Neal, J. W., Nieva, J. J., Puri, S., Socinski, M. A., Thomas, C., Ross, E. A., Litwin, S., Clapper, M. L., & Treat, J. (2023). Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2023.05.003
Vancouver
Bodor JN, Patel JD, Wakelee HA, Levy BP, Borghaei H, Pellini B, et al. Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked. Clinical Lung Cancer. 2023. doi:10.1016/j.cllc.2023.05.003
BibTeX
@article{Bodor2023,
author = {Bodor, J Nicholas and Patel, Jyoti D and Wakelee, Heather A and Levy, Benjamin P and Borghaei, Hossein and Pellini, Bruna and Costello, Michael R and Dowell, Jonathan E and Finley, Gene and Huang, Chao H and Neal, Joel W and Nieva, Jorge J and Puri, Sonam and Socinski, Mark A and Thomas, Christian and Ross, Eric A and Litwin, Samuel and Clapper, Margie L and Treat, Joseph},
title = {Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked},
journal = {Clinical Lung Cancer},
year = {2023},
doi = {10.1016/j.cllc.2023.05.003}
}
EUVIMED